Table 2.
Initial laboratory investigations on admission.
| Normal reference range | Total, n = 124 | Survivor group, n = 83 | Non-survivor group, n = 41 | p value | |
|---|---|---|---|---|---|
| White blood cell (× 109/L) (IQR) | 3.50–9.50 | 5.05 (3.91–7.04) | 4.84 (3.78–5.77) | 6.81 (4.79–10.91) | < 0.001 |
| Neutrophil (× 109/L) (IQR) | 1.80–6.30 | 3.37 (2.47–6.13) | 2.96 (2.24–3.97) | 6.45 (3.83–9.70) | < 0.001 |
| Lymphocyte (× 109/L) (IQR) | 1.10–3.20 | 0.94 (0.73–1.39) | 1.17 (0.84–1.55) | 0.73 (0.51–1.01) | < 0.001 |
| Lymphocyte percentage (%) (IQR) | 20.0–50.0 | 19.8 (10.7–30.1) | 26.2 (18.2–33.2) | 9.5 (5.9–17.8) | < 0.001 |
| Hemoglobin (g/L) (IQR) | 115–150 | 131 (121–143) | 129 (121–142) | 136 (121–144) | 0.276 |
| Platelet (× 109/L) (IQR) | 125–350 | 164 (130–207) | 174 (139–216) | 153 (125–186) | 0.074 |
| C-reactive protein (mg/L) (IQR) | 0.00–8.00 | 16.60 (7.50–76.23) | 10.85 (5.76–24.80) | 78.11 (53.54–110.78) | < 0.001 |
| Total bilirubin (μmol/L) (IQR) | 3.0–20 | 10.2 (8.5–14.6) | 9.6 (8.3–12.5) | 11.9 (9.2–20.9) | 0.023 |
| Alanine aminotransferase (U/L) (IQR) | 5–35 | 31 (21–50) | 28 (17–47) | 33 (23–56) | 0.196 |
| Aspartate aminotransferase (U/L) (IQR) | 8–40 | 33 (24–50) | 27 (22–38) | 48 (36–64) | < 0.001 |
| Lactate dehydrogenase (U/L) (IQR) | 109–245 | 330 (202–520) | 222 (181–338) | 490 (363–636) | < 0.001 |
| Albumin (g/L) (IQR) | 33.0–55.0 | 33.9 (28.7–38.5) | 36.1 (33.6–39.7) | 28.1 (26.1–31.5) | < 0.001 |
| Serum creatinine (μmol/L) (IQR) | 41.0–81.0 | 72.0 (57.6–89.2) | 68.0 (55.3–81.4) | 78.3 (61.3–109.8) | 0.005 |
| d-dimer (mg/L) (IQR) | 0.00–0.50 | 0.56 (0.26–1.98) | 0.30 (0.22–0.53) | 1.98 (0.75–8.00) | < 0.001 |